| 1 | stemcelltherapyargentina | 18K | micro | low | | reel | 159 | 33 | 60.9 | positive | 2026-01-31 | stem cell therapy | 🔥 BTL Láser 6000HD en acción en @stemcelltherapyargentina, 📍Olivos, Mendoza y Rí... | No audio available | ↗ |
| 2 | stemcelltherapyargentina | 18K | micro | low | | post | 64 | 16 | 39.9 | neutral | 2025-09-23 | stem cell therapy | 🇦🇷En Argentina, las terapias orto-biológicas están revolucionando la medicina re... | No audio available | ↗ |
| 3 | stemcelltherapyargentina | 18K | micro | low | | reel | 78 | 5 | 32.1 | positive | 2025-12-05 | stem cell therapy | 🇦🇷Stem Cell Therapy Argentina® @stemcelltherapyargentina | The regulatory medicine of the difference between supposing and knowing is in the diagnostic. And in this Argentina we use the echography in all our medical consultations to evaluate in real time what is happening inside your body. For this we have two of the most powerful echographs in the market. All this so that you don't have to do studies elsewhere and all our centers. On the one hand we have the Echograph for Butterfly IQ that allows us to guide the treatment we do within an area like a kyrófana. And one of our new incorporations in the consultory is the Consona NS-AIS. Surely you don't know these words, but it is one of the most advanced technologies in the image for the consultory. With superior quality and deep structure analysis. I want you to understand that this is not a minor detail. It is part of the commitment with a much more advanced medicine. In this Argentina we do not do blind treatments. If you want to experience it with your own eyes, send us a message and schedule your consultation. In this way we will be able to start working and thus improve your quality of life. | ↗ |
| 4 | stemcelltherapyargentina | 18K | micro | low | | reel | 66 | 6 | 20.9 | negative | 2026-01-13 | stem cell therapy | El Dr. Matías Fernández Viña nos cuenta cómo las terapias regenerativas fueron c... | I think that Medici and Regenerative have made a difference, the orthopedic therapies have made a difference to the rest of the other therapies, because having less support from the industry in the production of a drug, which now has more intention of that, the doctor had to do it a little more alone, trying to recruit the evidence that he could, to do all the therapeutic accompaniment with the patient with a lot of effort, and that led to obviously there being more lentitude in the development. But now that there is much more interest in the industry, there is much more support in the devices closed, there is support in more regulatory issues, I think that it begins to have a sense. In fact, if you look at the publications from the development of mesenchymals with NANI CAPLA in 1990, there were very few publications, and today, 25, we are talking about comparative publications with medicines like Betametason, Adyclophenac, with mesenchymal cells. That speaks of the fact that there is a huge growth in the industry in these therapies. | ↗ |